OptimizeRx (NASDAQ:OPRX) Given New $13.00 Price Target at B. Riley

OptimizeRx (NASDAQ:OPRX) had its target price reduced by B. Riley from $17.00 to $13.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently commented on OPRX. Stifel Nicolaus reduced their price target on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. William Blair reiterated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and issued a $16.00 target price (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Royal Bank of Canada dropped their price objective on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Finally, Barclays dropped their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.19.

OptimizeRx Trading Up 2.3 %

NASDAQ:OPRX opened at $4.94 on Tuesday. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm’s fifty day moving average is $5.31 and its 200-day moving average is $7.69. The firm has a market cap of $91.00 million, a P/E ratio of -3.71 and a beta of 1.34.

Insider Transactions at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of OptimizeRx stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC lifted its stake in OptimizeRx by 5.1% in the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after acquiring an additional 89,377 shares during the period. Rice Hall James & Associates LLC lifted its position in OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after buying an additional 119,306 shares during the period. Dimensional Fund Advisors LP grew its position in shares of OptimizeRx by 12.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock worth $3,241,000 after buying an additional 35,957 shares during the period. Essex Investment Management Co. LLC lifted its position in OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock valued at $1,868,000 after acquiring an additional 72,672 shares during the period. Finally, Bullseye Asset Management LLC grew its holdings in OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after purchasing an additional 76,458 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.